Compare Sanofi SA (SNY) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Sanofi SA trades at $43.14 (market cap $104.06B), while iShares 10 20 Year Treasury Bond ETF trades at $96.05. The key difference: Sanofi SA pays a 5.61% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and Sanofi SA is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SNY | TLH | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | Fixed Income |
52-Week High | $52.34 | $105.36 |
52-Week Low | $41.33 | $96.08 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
TLH trades at $96.52, down 0.09% on the day, with a bearish technical signal from moving averages but a neutral reading from oscillators. Recent corporate actions include dividend payments scheduled for 2026. Key support and resistance levels are tightly clustered around $96-$97. Financial ratios such as P/E, P/S, and ROE are not provided in the current data snapshot.
The outlook for TLH is clouded by the lack of recent fundamental data, making valuation difficult. Investment opportunity hinges on future earnings clarity and dividend sustainability. Risks include market volatility, macroeconomic pressures from rising bond yields and oil prices, and potential impacts from geopolitical tensions on broader equity sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
